Table 2

Change in MRI parameters from baseline to Year 3 by IFN β-1a dosage

MRI Parameter


T2 lesion volume

T1 Gd+ lesion volume

T1 black hole volume

IFN β-1a, 22 μg sc tiw

IFN β-1a, 44 μg sc tiw

IFN β-1a, 22 μg sc tiw

IFN β-1a, 44 μg sc tiw

IFN β-1a, 22 μg sc tiw

IFN β-1a, 44 μg sc tiw


Absolute change, mm3

N

72

86

70

84

71

85

Mean (SD)

−174.9 (1609.8)

−1037.2 (3863.3)

−23.5 (198.5)

−68.8 (316.3)

64.5 (608.5)

−196.5 (1311.9)

Median

−81.6

−169.7

0.0

0.0

0.0

−25.3

Q1, Q3

−654.5, 126.8

−1133.3, 13.5

0.0, 0.0

0.0, 0.0

−40.3, 92.5

−209.4, 26.8

P value

0.092

0.472

0.017

Percentage change

N

72

86

15*

19*

59*

73*

Mean (SD)

−4.5 (27.3)

−10.2 (38.9)

−54.2 (177.5)

−65.4 (127.9)

10.3 (49.3)

−7.8 (79.1)

Median

−3.4

−12.1

−100.0

−100.0

1.5

−16.1

Q1, Q3

−14.5, 4.3

−30.6, 2.8

−100.0, −100.0

−100.0, −100.0

−10.6, 23.2

−50.5, 19.0

P value

0.025

0.495

0.002


Gd+, gadolinium-enhancing; IFN, interferon; sc, subcutaneously; tiw, three times weekly.

*Percentage change was not calculated for patients with a lesion volume of 0 mm3 at baseline.

Bastianello et al. BMC Neurology 2011 11:125   doi:10.1186/1471-2377-11-125

Open Data